HK1199095A1 - Methods for monitoring responsiveness to anti-smad7 therapy smad7 - Google Patents
Methods for monitoring responsiveness to anti-smad7 therapy smad7Info
- Publication number
- HK1199095A1 HK1199095A1 HK14112438.9A HK14112438A HK1199095A1 HK 1199095 A1 HK1199095 A1 HK 1199095A1 HK 14112438 A HK14112438 A HK 14112438A HK 1199095 A1 HK1199095 A1 HK 1199095A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- smad7
- methods
- therapy
- monitoring responsiveness
- responsiveness
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 230000004043 responsiveness Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ecology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11425234 | 2011-09-15 | ||
| US201161576556P | 2011-12-16 | 2011-12-16 | |
| PCT/EP2012/068146 WO2013037970A1 (en) | 2011-09-15 | 2012-09-14 | Methods for monitoring responsiveness to anti-smad7 therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1199095A1 true HK1199095A1 (en) | 2015-06-19 |
Family
ID=47882658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112438.9A HK1199095A1 (en) | 2011-09-15 | 2014-12-10 | Methods for monitoring responsiveness to anti-smad7 therapy smad7 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9791442B2 (es) |
| EP (2) | EP2748611B1 (es) |
| JP (1) | JP6389122B2 (es) |
| KR (1) | KR102099990B1 (es) |
| CN (1) | CN104040349B (es) |
| AU (1) | AU2012307336B2 (es) |
| CA (1) | CA2848595A1 (es) |
| ES (1) | ES2617200T3 (es) |
| HK (1) | HK1199095A1 (es) |
| MX (1) | MX350087B (es) |
| RU (1) | RU2678450C2 (es) |
| WO (1) | WO2013037970A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| PT2364360T (pt) | 2008-11-13 | 2017-06-27 | Nogra Pharma Ltd | Composições em sentido reverso e métodos de as fabricar e utilizar |
| NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| MX363746B (es) * | 2013-03-15 | 2019-04-01 | Nogra Pharma Ltd | Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. |
| US20160139123A1 (en) * | 2013-07-12 | 2016-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid |
| KR20170005058A (ko) * | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| KR20170069262A (ko) * | 2014-10-17 | 2017-06-20 | 노그라 파마 리미티드 | Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 |
| EP3213070A2 (en) * | 2014-10-17 | 2017-09-06 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| MA41271A (fr) * | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| CN108139385A (zh) * | 2015-07-27 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎症性肠病的方法 |
| EP3356530A4 (en) * | 2015-09-30 | 2019-04-10 | Celgene Alpine Investment Company II, LLC | TLR MODULATORS AND ASSOCIATED METHODS OF USE |
| CA3000569A1 (en) * | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| WO2017147276A1 (en) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
| WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
| US11619832B2 (en) * | 2018-03-08 | 2023-04-04 | Coopervision International Limited | Identification of contact lens wearers predisposed to contact lens discomfort |
| CN110082538B (zh) * | 2019-04-19 | 2021-12-03 | 中山大学附属第六医院 | CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| RU2185627C2 (ru) * | 2000-09-11 | 2002-07-20 | Новосибирская государственная медицинская академия | Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца |
| SI1456380T1 (sl) | 2001-11-02 | 2012-11-30 | Giuliani Int Ltd | Smad inhibitorji za zdravljenje cns bolezni |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US20090275496A1 (en) * | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| EP1913387B1 (en) * | 2005-08-02 | 2016-01-20 | Centenary Institute of Cancer Medicine & Cell Biology | Method for identifying regulatory t cells |
| WO2007104145A1 (en) * | 2006-03-10 | 2007-09-20 | Mount Sinai Hospital | Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover |
| EP2167647A2 (en) * | 2007-06-13 | 2010-03-31 | La Jolla Institute For Allergy And Immunology | Regulatory t cells and methods of making and using same |
| JPWO2009107785A1 (ja) | 2008-02-28 | 2011-07-07 | シスメックス株式会社 | Ｉｌ−１７産生ヘルパーｔ細胞検出用マーカー及びｉｌ−１７産生ヘルパーｔ細胞の検出方法 |
| JP2010051307A (ja) | 2008-07-28 | 2010-03-11 | Eisai R & D Management Co Ltd | Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法 |
| PT2364360T (pt) | 2008-11-13 | 2017-06-27 | Nogra Pharma Ltd | Composições em sentido reverso e métodos de as fabricar e utilizar |
| DK2452194T3 (en) | 2009-07-10 | 2015-11-30 | Transgene Sa | Biomarker PATIENT SELECTION AND RELATED PRACTICES |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| MX363746B (es) | 2013-03-15 | 2019-04-01 | Nogra Pharma Ltd | Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| KR20170005058A (ko) | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| KR20170069262A (ko) | 2014-10-17 | 2017-06-20 | 노그라 파마 리미티드 | Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 |
| EP3213070A2 (en) | 2014-10-17 | 2017-09-06 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| CA3000569A1 (en) | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
-
2012
- 2012-09-14 WO PCT/EP2012/068146 patent/WO2013037970A1/en active Application Filing
- 2012-09-14 US US14/344,969 patent/US9791442B2/en not_active Expired - Fee Related
- 2012-09-14 CA CA2848595A patent/CA2848595A1/en not_active Abandoned
- 2012-09-14 EP EP12759150.1A patent/EP2748611B1/en not_active Not-in-force
- 2012-09-14 AU AU2012307336A patent/AU2012307336B2/en not_active Ceased
- 2012-09-14 MX MX2014003295A patent/MX350087B/es active IP Right Grant
- 2012-09-14 JP JP2014530245A patent/JP6389122B2/ja not_active Expired - Fee Related
- 2012-09-14 CN CN201280056296.8A patent/CN104040349B/zh not_active Expired - Fee Related
- 2012-09-14 ES ES12759150.1T patent/ES2617200T3/es active Active
- 2012-09-14 EP EP16184629.0A patent/EP3165929A3/en not_active Ceased
- 2012-09-14 KR KR1020147009572A patent/KR102099990B1/ko active IP Right Grant
- 2012-09-14 RU RU2014114838A patent/RU2678450C2/ru not_active IP Right Cessation
-
2014
- 2014-12-10 HK HK14112438.9A patent/HK1199095A1/xx not_active IP Right Cessation
-
2017
- 2017-09-15 US US15/705,715 patent/US20180128829A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9791442B2 (en) | 2017-10-17 |
| EP2748611B1 (en) | 2016-11-23 |
| US20180128829A1 (en) | 2018-05-10 |
| MX350087B (es) | 2017-08-24 |
| KR102099990B1 (ko) | 2020-04-13 |
| JP6389122B2 (ja) | 2018-09-12 |
| EP3165929A2 (en) | 2017-05-10 |
| WO2013037970A1 (en) | 2013-03-21 |
| CN104040349B (zh) | 2017-07-04 |
| KR20140059859A (ko) | 2014-05-16 |
| US20150148245A1 (en) | 2015-05-28 |
| RU2678450C2 (ru) | 2019-01-29 |
| NZ719884A (en) | 2020-02-28 |
| CN104040349A (zh) | 2014-09-10 |
| EP3165929A3 (en) | 2017-06-21 |
| JP2014531584A (ja) | 2014-11-27 |
| RU2014114838A (ru) | 2015-10-20 |
| AU2012307336A1 (en) | 2014-03-27 |
| AU2012307336B2 (en) | 2017-08-24 |
| MX2014003295A (es) | 2014-05-28 |
| NZ622067A (en) | 2016-05-27 |
| EP2748611A1 (en) | 2014-07-02 |
| CA2848595A1 (en) | 2013-03-21 |
| ES2617200T3 (es) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1199095A1 (en) | Methods for monitoring responsiveness to anti-smad7 therapy smad7 | |
| HK1243488A1 (zh) | 檢測治療性外來體的方法 | |
| EP2906697A4 (en) | METHODS OF MONITORING C9ORF72 EXPRESSION | |
| GB201110403D0 (en) | Monitoring of conduits | |
| EP2720719A4 (en) | METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS | |
| GB201411337D0 (en) | Seismic monitoring | |
| EP2768983A4 (en) | METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES | |
| EP2717855A4 (en) | PROCESSING METHODS | |
| GB201119608D0 (en) | Stimulation apparatus | |
| HK1189564A1 (zh) | 用於制動裝置的停止定序 | |
| EP2695315A4 (en) | PAGING CONTROL METHOD FOR STATIONARY DEVICES | |
| EP2637017A4 (en) | METHOD FOR MEASURING FILLING CAPACITY | |
| HK1201078A1 (en) | Noninvasive bioreactor monitoring | |
| GB201117538D0 (en) | Methods | |
| GB201111396D0 (en) | Monitoring of livestock | |
| GB201118302D0 (en) | Improvements to tyres | |
| ZA201502595B (en) | Therapeutic methods | |
| GB2496402B (en) | Monitoring apparatus | |
| EP2791165A4 (en) | PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY | |
| EP2776770A4 (en) | SYSTEM FOR MONITORING ELECTRODE CONSUMPTION | |
| ZA201403447B (en) | Responsiveness to angiogenesis inhibitors | |
| IL219622A (en) | Continuous process for making microcapsules | |
| EP2667931A4 (en) | PACING PROCESS FOR MAINTAINING THE REACTION OF CELLS | |
| IL231164A0 (en) | Responsiveness to angiogenesis inhibitors | |
| EP2756023A4 (en) | PROCESS FOR PREPARING SEMICRISTALLINE POLYLACTIDES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210911 |